Biotech entity
Every one of those 1 sits in a single category, clinical-trial. DehydraTECH is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 4 original sources each. GLP-1-A26-1 appears in 1 tracked Biotech story from July 12, 2026.
Last mentioned: Jul 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, clinical-trial. DehydraTECH is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 4 original sources each. GLP-1-A26-1 appears in 1 tracked Biotech story from July 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering GLP-1-A26-1. Shared-story counts are live from our verified record — not editorial picks.
Lexaria Bioscience commenced dosing in its GLP-1 animal study aiming to outperform Novo Nordisk’s SNAC-based oral delivery. With 11 arms and three new patent filings, the biotech targets differentiation in the booming GLP-1 sector.
GLP-1-A26-1 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
